GoodRx Holdings, Inc. Class A Common Stock (GDRX) is a publicly traded Healthcare sector company. As of November 10, 2026, GDRX trades at $3.57 with a market cap of $1.20B and a P/E ratio of 67.30. GDRX moved -2.19% today. Year to date, GDRX is +32.87%; over the trailing twelve months it is +17.49%. Its 52-week range spans $1.77 to $5.81. Analyst consensus is neutral with an average price target of $4.08. Rallies surfaces GDRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GoodRx files late 10-Q as revenue restatements and control weaknesses remain unresolved: GoodRx filed a non-timely third-quarter 2026 10-Q while completing restatements of first- and second-quarter financial statements. It expects one or more material weaknesses in internal controls and plans to release results and file the report within a five-calendar-day extension period.
| Metric | Value |
|---|---|
| Price | $3.57 |
| Market Cap | $1.20B |
| P/E Ratio | 67.30 |
| EPS | $0.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.81 |
| 52-Week Low | $1.77 |
| Volume | 1.50K |
| Avg Volume | 0 |
| Revenue (TTM) | $785.23M |
| Net Income | $16.25M |
| Gross Margin | 0.00% |
6 analysts cover GDRX: 0 strong buy, 2 buy, 2 hold, 2 sell, 0 strong sell. Consensus rating is neutral. Average price target: $4.08.